Taro Pharmaceuticals U.S.A., Inc.
Dedicated to maintaining the highest standard of quality, safety and excellence.
Established in 1950 Taro Pharmaceuticals Industries Ltd. has been a leader in the generic dermatological space with a portfolio of 283 SKU’s and growing. Taro’s portfolio features topline products such as Nystatin and Triamcinolone Acetonide Cream, Diflorasone Diacetate Ointment, and Betamethasone Dipropionate Cream.
Taro has recently entered into additional markets such as CNS treating seizure with Clobazam Tablets, treating depression with Fluoxetine Tablets, and more to come.
Taro also has an OTC market portfolio with topline products such as Terbinafine HCl Cream, Loratadine Oral Solution, and Cetirizine Oral Solution.
Taro is committed to Narrow Therapeutic Index (NTI) drugs and has had much success with marketing their approved products such as Carbamazepine, Warfarin, and Phenytoin.
Taro has been manufacturing high quality topical and solid dosage products over the past 50 years and is actively extending its reach into the ophthalmic market.
Taro is committed to delivering reliable products and reaching the sky with the company’s innovative R&D center located in Haifa, Israel which focuses on improving drug formulations to provide complete drug absorption, faster onset action, and easier dosing regimens as well as repurposing of existing molecules that have proven safety record. All efforts done by Taro are keeping the patient in mind and helping provide a better quality of life by producing easier and safer products to use